On October 14, 2019 Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, reported its participation at two upcoming investor conferences (Press release, Flex Pharma, OCT 14, 2019, View Source [SID1234540980]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will provide an overview of Salarius’ business during a live presentation at The Microcap Rodeo taking place October 15 – 16, 2019 in Austin, TX. Salarius’ management will be available to participate in one-on-one meetings during the event with investors who are registered to attend the conference. On October 17, 2019, management will participate in a panel at the Oppenheimer Oncology Summit in Houston, TX.

Details on Salarius’ participation in the conferences are as follows:

Event: The Microcap Rodeo

Date: Wednesday, October 16, 2019

Time: 10:55 a.m. CT

Location: Meeting Room 415A
Hilton Austin – Downtown, Street, Austin TX

Live Webcast: View Source

Event: Oppenheimer Oncology Summit

Panel: The Evolving Strategies in Targeted Drug Development

Date: Thursday, October 17, 2019

Time: 9:45 a.m. to 10:35 a.m. CT

Location: Rotary House Hotel, Houston, TX